BRCA2 and neoplasm: Men harboring BRCA2 or MMR mutations may benefit from earlier prostate-specific antigen (PSA) testing or colonoscopic screening, whereas azoospermic men with Y-chromosome deletions could undergo periodic testicular ultrasonography and serum tumor-marker assessment.